PMN310 Shows Zero ARIA-E in Alzheimer's Trial, Early Biomarker Signal Positive
PMN has more than doubled off its 52-week low of $6.27 on elevated volume (2.0× avg).
Summary
ProMIS Neurosciences reported positive blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer's disease. No cases of ARIA-E were observed across all genotypes, including high-risk APOE4 homozygotes, and total ARIA was just 4.4% (all mild, asymptomatic microhemorrhages). Blinded biomarker data showed 68.5% of patients had a decline in plasma pTau217 and 62.5% a decline in CSF MTBR-tau243, consistent with target engagement and a potential drug effect. The trial remains blinded with 12-month topline efficacy data expected in Q1 2027. This follows the company's $75.5 million private placement in May 2026, which extended its cash runway. The safety profile directly addresses the key barrier to amyloid-targeting therapies—ARIA risk—and could differentiate PMN310 from approved drugs.
At the time of this announcement, PMN was trading at $14.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $105.1M. The 52-week trading range was $6.27 to $27.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.